The arthus reaction in rats, a possible test for anti-inflammatory and antirheumatic drugs

1979 ◽  
Vol 9 (2) ◽  
pp. 184-189 ◽  
Author(s):  
Lawrence R. Pflum ◽  
Mary Lee Graeme
Keyword(s):  
Arthus Reaction ◽  
Antirheumatic Drugs ◽  
Anti Inflammatory

scholarly journals Recent Findings on Thymoquinone and its Applications as a Nanocarrier for the Treatment of Cancer and Rheumatoid Arthritis

Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 775
Author(s):  
Ravi Raj Pal ◽  
Vasundhara Rajpal ◽  
Priya Singh ◽  
Shubhini A. Saraf
Keyword(s):  
Rheumatoid Arthritis ◽  
Aqueous Solubility ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Anticancer Efficacy ◽  
Drug Deposition ◽  
Anticancer Properties ◽  
Enhanced Permeability And Retention ◽  
Anti Inflammatory ◽  
Energy Dependent

Cancer causes a considerable amount of mortality in the world, while arthritis is an immunological dysregulation with multifactorial pathogenesis including genetic and environmental defects. Both conditions have inflammation as a part of their pathogenesis. Resistance to anticancer and disease-modifying antirheumatic drugs (DMARDs) happens frequently through the generation of energy-dependent transporters, which lead to the expulsion of cellular drug contents. Thymoquinone (TQ) is a bioactive molecule with anticancer as well as anti-inflammatory activities via the downregulation of several chemokines and cytokines. Nevertheless, the pharmacological importance and therapeutic feasibility of thymoquinone are underutilized due to intrinsic pharmacokinetics, including short half-life, inadequate biological stability, poor aqueous solubility, and low bioavailability. Owing to these pharmacokinetic limitations of TQ, nanoformulations have gained remarkable attention in recent years. Therefore, this compilation intends to critically analyze recent advancements in rheumatoid arthritis and cancer delivery of TQ. This literature search revealed that nanocarriers exhibit potential results in achieving targetability, maximizing drug internalization, as well as enhancing the anti-inflammatory and anticancer efficacy of TQ. Additionally, TQ-NPs (thymoquinone nanoparticles) as a therapeutic payload modulated autophagy as well as enhanced the potential of other drugs when given in combination. Moreover, nanoformulations improved pharmacokinetics, drug deposition, using EPR (enhanced permeability and retention) and receptor-mediated delivery, and enhanced anti-inflammatory and anticancer properties. TQ’s potential to reduce metal toxicity, its clinical trials and patents have also been discussed.

Use of the reversed passive arthus reaction as a test for anti-inflammatory agents

1975 ◽  
Vol 5 (1) ◽  
pp. 39-47 ◽  
Author(s):  
Marvin B. Goldlust ◽  
William F. Schreiber
Keyword(s):  
Arthus Reaction ◽  
Anti Inflammatory

Anti-allergic and anti-inflammatory properties of Zizyphus mauritiana root bark

2015 ◽  
Vol 6 (9) ◽  
pp. 2975-2983 ◽  
Author(s):  
Suhas Talmale ◽  
Arti Bhujade ◽  
Mandakini Patil
Keyword(s):  
Complement System ◽  
Anaphylactic Shock ◽  
Root Bark ◽  
Arthus Reaction ◽  
Zizyphus Mauritiana ◽  
Cox 2 ◽  
Anti Inflammatory ◽  
The Complement System ◽  
Cox 1

The MAF, a fraction with potent anti-allergic and anti-inflammatory compounds, is isolated fromZizyphus mauritianaroot bark. The MAF has an excellent ability to inhibit the complement system, COX-1, COX-2 and 5-LOX and has the potential to prevent anaphylactic shock and the Arthus reaction.

scholarly journals Method for Assessing Therapeutic Potential of Anti-inflammatory Antirheumatic Drugs in Rheumatoid Arthritis

BMJ ◽  
1973 ◽  
Vol 2 (5868) ◽  
pp. 685-688 ◽  
Author(s):  
P. Lee ◽  
J. Webb ◽  
J. Anderson ◽  
W. W. Buchanan
Keyword(s):  
Rheumatoid Arthritis ◽  
Therapeutic Potential ◽  
Antirheumatic Drugs ◽  
Anti Inflammatory

scholarly journals New Therapeutic Approaches for the Treatment of Rheumatoid Arthritis may Rise from the Cholinergic Anti-Inflammatory Pathway and Antinociceptive Pathway

2010 ◽  
Vol 10 ◽  
pp. 2248-2253 ◽  
Author(s):  
Xiao Hua Pan ◽  
Jianxin Zhang ◽  
Xiaowei Yu ◽  
Ling Qin ◽  
Ligeng Kang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Therapeutic Approaches ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Drug Discovery And Development ◽  
New Therapeutic Approaches ◽  
Inflammatory Drugs ◽  
Disease Modifying ◽  
Anti Inflammatory ◽  
Current Stage

Due to the complex etiology of rheumatoid arthritis (RA), it is difficult to be completely cured at the current stage although many approaches have been applied in clinics, especially the wide application of nonsteroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). New drug discovery and development via the recently discovered cholinergic anti-inflammatory and antinociceptive pathways should be promising. Based on the above, the nicotinic acetylcholine receptor agonists maintain the potential for the treatment of RA. Therefore, new therapeutic approaches may rise from these two newly discovered pathways. More preclinical experiments and clinical trials are required to confirm our viewpoint.

Sign in / Sign up

Export Citation Format

Share Document